Jonathan Goodman, MPhil

Immune checkpoint inhibitors prolonged survival when compared with chemotherapy.

Response endpoints were not strongly correlated with overall survival at the trial level.

About 31% of the articles analyzed contained information classified as harmful.

Surgery was an independent predictor of overall survival.

Researchers sought to determine whether adding brentuximab vedotin to chemotherapy would be safe and effective in pediatric patients with ALCL.

The results suggest a link, but more research is needed.

Nab-paclitaxel was associated with an improvement in long-term overall survival.

The tumor lysis syndrome risk decreased for 84.6% of patients in the ibrutinib/venetoclax group.

Six patients experienced a grade 5 treatment-related adverse event.

Adding isatuximab to pomalidomide and dexamethasone improved progression-free survival (PFS) and PFS2.